N/A
Completed N=312
Predicting Severe Toxicity of Targeted Therapies in Elderly Patients With Cancer
Source: ClinicalTrials.gov NCT02751827 ↗Enrolled (actual)
312
Serious AEs
42.4%
Results posted
Jun 2021
Primary outcomePrimary: Rate of Severe Toxicity — 14; 75; 43 Participants
Summary
In order to assess the important issue of the safety of antiangiogenic TKI in geriatric population we set up this project which aims to identify, among clinical, biological, pharmacokinetic data, predictive factors for severe toxicity of antiangiogenic TKI (sunitinib, sorafenib, pazopanib, regorafenib, axitinib) in patients over 70 year-old.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Rate of Severe Toxicity |
14; 75; 43 | — |
Eligibility Criteria
Inclusion Criteria
- Age ≥ 70 years
- Treatment with pazopanib, regorafenib, sorafenib, sunitinib,axitinib in the context of market authorization
- Voluntary signed and dated written informed consent prior to any study specific procedure.
Exclusion Criteria
- Patient treated in a context of clinical trial
- Patient with altered mental status or psychiatric disorder that, in the opinion of the investigator, would preclude a valid patient consent
Data sourced from ClinicalTrials.gov (NCT02751827). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.